European Banking M&A
UniCredit's major stake in Commerzbank signals the start of European banking consolidation. Our experts have selected companies positioned to benefit from this wave, including potential M&A targets and the investment banks that will earn fees from these deals.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Deutsche Bank AG
DB
Current price
$36.36
As Germany's largest bank and a direct competitor to Commerzbank, Deutsche Bank is at the center of any German or European consolidation talk, either ...
As Germany's largest bank and a direct competitor to Commerzbank, Deutsche Bank is at the center of any German or European consolidation talk, either as an acquirer or a potential merger partner.
Join Nemo FREE today and unlock every stock.
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
UniCredit's move into Commerzbank has triggered what could be a major wave of European banking consolidation. After years of fragmentation, European banks are finally looking to merge across borders to gain scale, improve efficiency, and boost profits. This theme captures both sides of this trend.
What You Need to Know
This group includes two types of companies: major European banks likely to participate in mergers (as buyers or sellers), and global investment banks that will earn advisory fees from these deals. The timing is significant as regulatory attitudes toward cross-border banking mergers have become more favorable.
Why These Stocks
These companies were carefully selected to provide direct exposure to European banking consolidation. We've included major banks from Germany, Spain, and the UK that could be central players in merger activity, alongside top advisory firms positioned to benefit from increased deal flow.
Group Performance Snapshot
Stocks Rated Buy by Analysts
6 of 15 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 1.9% return last month.
Why You'll Want to Watch These Stocks
Banking's Big Moment
European banking is undergoing its biggest shake-up in decades. UniCredit's bold move marks the beginning of a consolidation wave that could reshape the entire sector and create significant shareholder value.
Double-Sided Opportunity
This theme gives you exposure to both sides of the M&A equation: the banks involved in mergers that could see valuations rise, and the advisory firms that will collect significant fees from facilitating these complex deals.
A Long-Awaited Catalyst
European banking consolidation has been talked about for years but faced regulatory hurdles. Now those barriers are falling, creating a rare moment when a previously fragmented sector can finally integrate and improve profitability.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.